Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CD69 | Q07108 | 1/20 | 0.42 |
| ▸ | PTN | P21246 | 1/20 | 0.42 |
| ▸ | MDK | P21741 | 1/20 | 0.42 |
| ▸ | BDNF | P23560 | 1/20 | 0.42 |
| ▸ | FGF1 | P05230 | 1/20 | 0.40 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.40 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150356 | 0.90 | CA2 (0.47) | CA2CA9CA1ALDH1A1THRB | |
| SCHEMBL7150359 | 0.90 | CA2 (0.47) | CA2CA9CA1ALDH1A1THRB | |
| SCHEMBL16998721 | 0.86 | ALDH1A1 (0.55) | CA2CA9CA1ALDH1A1THRB | |
| SCHEMBL15965653 | 0.85 | MAPK1 (0.45) | CA2CA9CA1F10ALDH1A1 | |
| SCHEMBL15966248 | 0.85 | MAPK1 (0.45) | CA2CA9CA1F10ALDH1A1 | |
| SCHEMBL23631128 | 0.85 | MAPK1 (0.45) | CA2CA9CA1F10ALDH1A1 | |
| SCHEMBL22362645 | 0.85 | MAPK1 (0.45) | CA2CA9CA1F10ALDH1A1 | |
| SCHEMBL20474503 | 0.85 | MAPK1 (0.45) | CA2CA9CA1F10ALDH1A1 | |
| SCHEMBL30089326 | 0.85 | MAPK1 (0.45) | CA2CA9CA1F10ALDH1A1 | |
| SCHEMBL17689074 | 0.85 | MAPK1 (0.45) | CA2CA9CA1F10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190665-A1 | Sugar Derivatives Comprising Sulfur-Containing Moieties And Methods Of Making Same And Methods Of Using The Same For The Treatment Of MPS IIIC | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-07-06 | — | — | US | disclosed |
| US-9598438-B2 | Sugar derivatives comprising sulfur-containing moieties and methods of making same and methods of using the same for the treatment of MPS IIIC | AMICUS THERAPEUTICS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150225420-A1 | Sugar Derivatives Comprising Sulfur-Containing Moieties And Methods Of Making Same and Methods of Using the Same for the Treatment of MPS IIIC | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225420-A1 | Sugar Derivatives Comprising Sulfur-Containing Moieties And Methods Of Making Same and Methods of Using the Same for the Treatment of MPS IIIC | MPST, STS, GALC | CA2 2677/4885CA9 1323/4885CA1 2905/4885 |
| US-20170190665-A1 | Sugar Derivatives Comprising Sulfur-Containing Moieties And Methods Of Making Same And Methods Of Using The Same For The Treatment Of MPS IIIC | MPST, STS, GALC | CA2 2677/4885CA9 1323/4885CA1 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.